Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States

Completed

• Conditions: Hypercholesterolemia

• Registration Number: NCT01031277
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations:

* Primary/secondary prevention patients.

* Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:

* Primary/secondary prevention patients.

* Patients with metabolic syndrome.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-11
• Study First Submitted: 2009-12-11
• Study First Submitted QC: 2009-12-11
• Study First Posted: 2009-12-14
• Primary Completion: 2010-07
• Study Completion: 2010-07
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-24
• Last Update Posted: 2011-05-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Race
• On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
• Subject must sign informed consent

Exclusion Criteria

• Subjects who are unwilling or unable to provide informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country.	6 months- One visit only, no follow up visits.

Secondary Outcome Measures

Name	Time	Method
Proportion patients on lipid-lowering drugs (LLD) reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III in subgroups: Primary/secondary prevention patients; Patients with metabolic syndrome ( NCEP III).	6 months- One visit only, no follow up visits.
Proportion patients on LLD reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in sub-populations: Primary/secondary prevention patients; Patients with metabolic syndrome.	6 months- One visit only, no follow up visits.
To identify determinants (e.g. patient and physician characteristics, country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia.	6 months- One visit only, no follow up visits.

Trial Locations

Locations (1)

Research Site; 🇦🇪 Abu Dhabi, United Arab Emirates